Medtronic, Inc. (MDT) Reports In-Line Q3 EPS of 84c; Reaffirms FY12 Sales Outlook
Tweet
Share
E-mailGet Alerts MDT Hot Sheet
Price: $94.17 +1.15%
Revenue Growth %: +5.3%
Financial Fact:
Net sales: 4.32B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.3%
Financial Fact:
Net sales: 4.32B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Medtronic, Inc. (NYSE: MDT) reported Q3 EPS of $0.84, in-line with the analyst estimate of $0.84. Revenue for the quarter came in at $3.92 billion versus the consensus estimate of $3.99 billion.
Reaffirms its FY12 sales guidance, sees EPS of $3.44-$3.47.
For earnings history and earnings-related data on Medtronic, Inc. (MDT) click here.
Reaffirms its FY12 sales guidance, sees EPS of $3.44-$3.47.
For earnings history and earnings-related data on Medtronic, Inc. (MDT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
